Skip to content

AYTU BIOPHARMA, INC

AYTU

CIK 0001385818

← back to feed
Revenue (TTM)
$59.92M
+1.8% YoY Q3 Apr 2026
Net Income (TTM)
−$10.24M
+14.4% YoY Q3 Apr 2026
EPS Diluted (TTM)
−$1.45
+93.1% YoY Q3 Apr 2026
Gross Margin
65.4%
Q3 Apr 2026
Operating Margin
-8.5%
Q3 Apr 2026
Net Margin
-17.1%
Q3 Apr 2026
Free Cash Flow (TTM)
−$11.31M
Q3 Apr 2026
Cash
$26.72M
Q3 Apr 2026
Total Debt
$13.56M
Q3 Apr 2026
Shares Outstanding
10.73M sh
Q3 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings